Orphan Drug Focus Small biotech regulatory advisory service with expertise in orphan drug designations and regulatory strategy, presenting a targeted opportunity to offer advisory packages to biopharma clients pursuing rare disease therapies.

Regulatory Alignment Strong emphasis on FDA and EMA meeting preparation and regulatory strategy could be sold as a concierge service to biotech firms seeking efficient, compliant pathways for orphan and pediatric rare disease programs.

Strategic Partnerships Experience connecting patients, advocacy groups, and key opinion leaders positions Haffner Associates as a partner for market access and payer strategy discussions, enabling expansion into sponsorships and registry initiatives.

Boutique Scale Small team with specialized capabilities suggests high-touch, customizable consulting retainers or project-based engagements for early-stage and mid-stage biotech companies needing regulatory and strategic support without large firm overhead.

Financial Leverage Revenue in the lower multi-millions range indicates potential upsell into broader consulting bundles, including regulatory intelligence, clinical strategy, and payer/market access planning for orphan and pediatric programs.